New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Read more
Alectinib shows promise in phase 3 ALINA trial for non-small cell lung cancer By Investing.com Read more